Biovac has retained a R5.3bn contract to supply the State with Hexaxim, the six-in-one shot for infants in the national childhood immunisation programme. – Business Day (14 May 2026) The tender is set to begin on 1 January 2027.
The contract is vital to Biovac's financial stability as it relies heavily on state business for its ongoing operations.
In 2023 Biovac had to retrench staff after the Department of Health rejected its pneumonia vaccine in favour of cheaper imported alternatives from India instead.
The local subsidiary of Indian generic drug manufacturer Cipla won contracts worth a combined R1.1bn to supply vaccines against pneumonia, rotavirus, and hepatitis B.